2021-01-15

A thesis based on the Karma Cohort and focusing on breast cancer risk prediction and prevention was defended 15 January, 2021

The thesis included a paper describing a unique tool, STRATUS, for measuring mammographic density regardless of type of image and vendor. This tool and additional mammographic features was used for generating a risk prediction tool and described below, published 20-09-08 (please see below). The thesis also described the Karisma trial where lower doses of tamoxifen were tested. In short, 1,440 women were randomised to placebo, 1, 2.5, 5, 10 and 20 mg and it turned out that 2.5 mg could be equally affective as 20 mg of tamoxifen but come with a 50% reduction in side effects (paper accepted for publication J Clin Oncology). Lastly, modelling the impact of a tamoxifen induced density decrease showed that the mammographic sensitivity would increase enabling even earlier detection of breast cancers and thereby a reduction in interval cancers by 24%.

A clinical model for identifying the short-term risk of breast cancer. Eriksson et al. Breast Cancer Reesearch, 2017. DOI: 10.1186/s13058-017-0820-y

Use of Low-Dose Tamoxifen to Increase Mammographic Screening Sensitivity in Premenopausal Women. Eriksson et al. Cancer. 2021. DOI: 10.3390/cancers13020302

Use of Low-Dose Tamoxifen to Increase Mammographic Screening Sensitivity in Premenopausal Women. Eriksson et al. Cancer. DOI: 10.3390/cancers13020302

Leave a Reply

Your email address will not be published. Required fields are marked *